Oncolys BioPharma Inc.
Announcement of sales commencement for Telomera-Syn® Note
Sales commencement of tumor-lytic virus Telomera-Syn® 注 in Japan. Sales partner FujiFilm Toyama Chemical, with initial delivery to medical institutions planned. A local therapeutic agent for esophageal cancer patients approved on June 8, expected to provide a new treatment option.
Key Figures
- Sales start: Telomera-Syn® note sales commencement (Unknown)
- Standard approval: June 8, 2026, Japan (Unknown)
- Sales partner: FujiFilm Toyama Chemical Co., Ltd. (Unknown)
AI要約
Section Header
This release announces the sales commencement of Telomera-Syn® 注 in Japan. It focuses on the approval date, sales partner, the distribution flow, and expanded treatment options for eligible patients. The significance of market entry as a new phase in our drug discovery business is emphasized in the CEO's message.
Section 2 Header
Looking ahead, expanding adoption by medical institutions, establishing a robust supply framework, and broadening clinical applicability to enhance treatment options are important. Building a distribution network through the sales partner and the progress of approvals are considered in order to aim for long-term market expansion.
Oncolys BioPharma Inc.
Company overview · Stock price · Financial data · All IR
